The UK’s research and development (R&D) funding agency ARIA has granted funds to anti-clinical research organisation (CRO) ...

The Phase I trial saw repeated oral doses of ARV-102 able to more than half the protein suspected to play a factor in ...

DCTs were readily adopted during the pandemic, with many believing they were more sustainable, but experts are now ...

Vividion Therapeutics has dosed the first subject in a Phase I trial of an oral inhibitor, VVD-159642, aimed at treating ...

Results from Lundbeck's open-label portion of the Pacific trial saw bexicaserin able to elicit seizure reduction in treatment ...

Desentum’s Phase I trial saw nearly all patients in the trial reaching their targeted maximum dose of pollen allergy vaccine, ...

The Phase II study found that lepodisiran significantly reduced levels of genetically inherited cardiovascular risk factor.

Higher doses of the company’s multiple sclerosis drug failed to show additional benefit in slowing rates of disability ...

AC Immune has reported additional interim safety and positive immunogenicity outcomes from its placebo-controlled Phase II ...

BioMarin has reported that the multi-centre Phase III PEGASUS trial of Palynziq (pegvaliase-pqpz) has met its primary ...

Initial results from the ongoing trial saw one patient achieving a complete response in the trial combining Tovecimig with ...

IgniteData has announced a partnership with AstraZeneca, MSK for launching the Archer tool for automation of EHR-to-EDC in a ...